Martin Wilson Sells 1,175 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Martin Wilson sold 1,175 shares of the business’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $13.05, for a total transaction of $15,333.75. Following the transaction, the general counsel now owns 63,560 shares in the company, valued at approximately $829,458. The trade was a 1.82 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Rocket Pharmaceuticals Trading Down 0.1 %

Shares of RCKT traded down $0.01 during trading hours on Monday, reaching $14.10. 1,205,582 shares of the company traded hands, compared to its average volume of 796,581. Rocket Pharmaceuticals, Inc. has a 12 month low of $12.62 and a 12 month high of $32.53. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -5.13 and a beta of 1.09. The company’s fifty day moving average price is $17.15 and its two-hundred day moving average price is $19.83. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its stake in Rocket Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 582 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Rocket Pharmaceuticals by 31.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,160 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 764 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of Rocket Pharmaceuticals during the 3rd quarter valued at about $108,000. SG Americas Securities LLC purchased a new stake in shares of Rocket Pharmaceuticals during the 3rd quarter valued at about $113,000. Finally, XTX Topco Ltd bought a new stake in shares of Rocket Pharmaceuticals during the 3rd quarter valued at $286,000. 98.39% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on RCKT shares. Leerink Partners lowered their price objective on Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 19th. Scotiabank began coverage on Rocket Pharmaceuticals in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $50.00 target price on the stock. Chardan Capital reissued a “buy” rating and set a $62.00 price objective on shares of Rocket Pharmaceuticals in a research report on Monday, November 18th. Canaccord Genuity Group reissued a “buy” rating and issued a $39.00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price target on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $51.00.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.